Alzamend Neuro partners with Mass General for Alzheimer's treatment trial [Yahoo! Finance]
Alzamend Neuro, Inc. (ALZN)
Company Research
Source: Yahoo! Finance
The trial will also include a cohort of healthy subjects to compare plasma and brain pharmacokinetics. Massachusetts General Hospital, affiliated with Harvard Medical School, will act as the contract research organisation for the study. The trial aims to determine the comparative increase in lithium levels within the brain and its structures between Alzheimer's patients and healthy subjects. By analysing lithium content in patients' brains during treatment, Alzamend aims to identify the minimum effective dose of AL001. The company believes this study will support regulatory safety standards through the Section 505(b)(2) pathway for the US Food and Drug Administration (FDA) approval. Alzamend has already completed a Phase IIA clinical trial, establishing a maximum tolerated dose for AL001. This dose, equivalent to 240mg of lithium carbonate taken three times daily, is designed to be safe for fragile populations without requiring therapeutic drug monitoring. Alzamend CEO
Show less
Read more
Impact Snapshot
Event Time:
ALZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALZN alerts
High impacting Alzamend Neuro, Inc. news events
Weekly update
A roundup of the hottest topics
ALZN
News
- Alzamend Neuro Issues Letter to StockholdersBusiness Wire
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress DisorderBusiness Wire
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder Business Wire
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar DisorderBusiness Wire
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
ALZN
Sec Filings
- 9/11/24 - Form 10-Q
- 8/14/24 - Form 4
- 8/1/24 - Form 4
- ALZN's page on the SEC website